FADS2 was found to be highly expressed in a subset of triple-negative breast cancer patients characterized by poorer prognoses 40; furthermore, donafenib was shown to downregulate FADS2, resulting in synergistic inhibition of hepatocellular carcinoma in both in vitro and in vivo models 41. This evidence concerns the gene FADS2 and hepatocellular carcinoma.